awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q40836385-7E58A366-0DC2-4D98-98BD-757594A2917C
Q40836385-7E58A366-0DC2-4D98-98BD-757594A2917C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q40836385-7E58A366-0DC2-4D98-98BD-757594A2917C
Infants born before 32 weeks of gestation or with respiratory disease are most likely to receive palivizumab in the Netherlands.
P2860
Q40836385-7E58A366-0DC2-4D98-98BD-757594A2917C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q40836385-7E58A366-0DC2-4D98-98BD-757594A2917C
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
3a85c45b36ee9d65212d315dda8f1d75911a417a
P2860
The cost effectiveness of palivizumab: a systematic review of the evidence.